Drug intelligence / Profile preview

Telmikshi-AM

Development stage
Phase 4
Lead developer
Mankind Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Telmikshi-AM is a fixed-dose combination pharmaceutical product marketed by Makshi Healthcare for the management of hypertension. It contains two active antihypertensive agents: telmisartan and amlodipine. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively binds to the angiotensin II type 1 (AT1) receptor, inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Amlodipine is a long-acting dihydropyridine calcium channel blocker (CCB) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and a reduction in systemic vascular resistance. By combining these two mechanisms, Telmikshi-AM provides a synergistic blood pressure-lowering effect, making it suitable for patients whose hypertension is not adequately controlled by monotherapy.

Brand names
Telmikshi-AM
Other names
Telmisartan + Amlodipine
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on Telmikshi-AM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telmikshi-AM.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call